Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A self-aggregating peptide: implications for the development of thermostable vaccine candidates

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The use of biomaterials has been expanded to improve the characteristics of vaccines. Recently we have identified that the peptide PH (1–110) from polyhedrin self-aggregates and incorporates foreign proteins to form particles. We have proposed that this peptide can be used as an antigen carrying system for vaccines. However, the immune response generated by the antigen fused to the peptide has not been fully characterized. In addition, the adjuvant effect and thermostability of the particles has not been evaluated.

          Results

          In the present study we demonstrate the use of a system developed to generate nano and microparticles carrying as a fusion protein peptides or proteins of interest to be used as vaccines. These particles are purified easily by centrifugation. Immunization of animals with the particles in the absence of adjuvant result in a robust and long-lasting immune response. Proteins contained inside the particles are maintained for over 1 year at ambient temperature, preserving their immunological properties.

          Conclusion

          The rapid and efficient production of the particles in addition to the robust immune response they generate position this system as an excellent method for the rapid response against emerging diseases. The thermostability conferred by the particle system facilitates the distribution of the vaccines in developing countries or areas with no electricity.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Type 1/Type 2 immunity in infectious diseases.

          T helper type 1 (Th1) lymphocytes secrete secrete interleukin (IL)-2, interferon-gamma, and lymphotoxin-alpha and stimulate type 1 immunity, which is characterized by intense phagocytic activity. Conversely, Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 and stimulate type 2 immunity, which is characterized by high antibody titers. Type 1 and type 2 immunity are not strictly synonymous with cell-mediated and humoral immunity, because Th1 cells also stimulate moderate levels of antibody production, whereas Th2 cells actively suppress phagocytosis. For most infections, save those caused by large eukaryotic pathogens, type 1 immunity is protective, whereas type 2 responses assist with the resolution of cell-mediated inflammation. Severe systemic stress, immunosuppression, or overwhelming microbial inoculation causes the immune system to mount a type 2 response to an infection normally controlled by type 1 immunity. In such cases, administration of antimicrobial chemotherapy and exogenous cytokines restores systemic balance, which allows successful immune responses to clear the infection.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            New adjuvants for human vaccines.

            Despite their obvious benefits, decades of research and hundreds of pre-clinical candidates, only a handful of adjuvants are approved for prophylactic vaccination of humans. The slow pace of development is due to a number of knowledge gaps, the most important of which is the complexity involved in designing adjuvants that are both potent and well tolerated. Recent advances in our understanding of innate immunity have led to the identification of immune pathways and adjuvant formulations more suitable for clinical advancement. One area of particular interest is the discovery of agonists that target the toll-like receptors. This review highlights recent progress of clinically approved vaccine adjuvants and identifies potential novel adjuvants that can broaden the development of new vaccines against infectious diseases. Copyright 2010 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Simply put: Vaccination saves lives

                Bookmark

                Author and article information

                Contributors
                lvaca@ifc.unam.mx
                Journal
                BMC Biotechnol
                BMC Biotechnol
                BMC Biotechnology
                BioMed Central (London )
                1472-6750
                21 January 2020
                21 January 2020
                2020
                : 20
                : 1
                Affiliations
                [1 ]ISNI 0000 0001 2159 0001, GRID grid.9486.3, Instituto de Fisiología Celular, , Universidad Nacional Autónoma de México, ; CDMX 04510 Mexico City, Mexico
                [2 ]ISNI 0000 0001 2159 0001, GRID grid.9486.3, Instituto de Investigaciones Biomédicas, , Universidad Nacional Autónoma de México, ; CDMX 04510 Mexico City, Mexico
                [3 ]ISNI 0000 0001 2159 0001, GRID grid.9486.3, Facultad de Medicina Veterinaria y Zootecnia, , Universidad Nacional Autónoma de México, ; CDMX 04510 Mexico City, Mexico
                [4 ]ISNI 0000000122986657, GRID grid.34477.33, Department of Physiology and Biophysics, , University of Washington School of Medicine, ; Seattle, WA 98124 USA
                Author information
                http://orcid.org/0000-0003-2266-4847
                Article
                592
                10.1186/s12896-019-0592-9
                6971912
                31959159
                20bd90fa-3e92-4d5a-ad58-3c193777901e
                © The Author(s). 2020

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 12 August 2019
                : 6 December 2019
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                Biotechnology
                vaccines,particles,self-assembling,thermostable,immunology
                Biotechnology
                vaccines, particles, self-assembling, thermostable, immunology

                Comments

                Comment on this article